title: PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
authors.affiliation: Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA dGenomics England, Queen Mary University of London, London, UK.
authors.forename: Alison E
authors.initials: AE
authors.lastname: Fohner
authors.forename: Ellen M
authors.initials: EM
authors.lastname: McDonagh
authors.forename: John P
authors.initials: JP
authors.lastname: Clancy
authors.forename: Michelle
authors.initials: M
authors.lastname: Whirl Carrillo
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D000627:Aminophenols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000819:agonists / Q000235:genetics*; D006801:Humans; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000627:Aminophenols; C505032:CFTR protein, human; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor